Longevity-adjacent
NAD+ and NAD precursors (NMN, NR)
Also known as: nicotinamide adenine dinucleotide, NMN, NR, Niagen
Plain-language summary
NAD+ is a coenzyme central to metabolism; NMN and NR are precursors sold as supplements to raise NAD+ for longevity and energy claims. They are not FDA-approved drugs.
Regulatory status
Compounded and unapproved products are not FDA-reviewed for safety, effectiveness, or quality.
Evidence snapshot
Limited. Supported mainly by small studies, early-phase trials, or indirect evidence. Conclusions are tentative.
How it works
NAD+ is required for energy metabolism and for enzymes such as sirtuins and PARPs; NMN and NR are precursors the body can convert to NAD+, and supplementation aims to counter age-related NAD+ decline.
Approved uses and researched uses
FDA-approved uses
None. This product has no FDA-approved use for the context described.
Researched (not approved) uses
- Raising NAD+ levels
- Metabolic and cardiovascular health
- Muscle and cognitive aging (early-stage research)
Researched uses are studied but not FDA-approved and may be off-label. This is not a recommendation to use them.
Known risks and uncertainties
Human studies of NR report good short-term tolerability, with occasional mild GI symptoms, flushing, or fatigue. Long-term safety, ideal dosing, and any real clinical benefit are not established, and supplement quality varies because these are not FDA-reviewed drugs.
Cautions and contraindications
No established clinical contraindications; caution is reasonable in pregnancy, breastfeeding, and active cancer given limited data, and supplement-drug interactions are not well characterized.
Consumer considerations
- Sold as supplements, not FDA-approved medicines, so disease or anti-aging claims are not FDA-verified.
- They can raise measured NAD+ levels, but that has not been shown to translate into longevity.
- Supplement potency and purity vary between brands.
- NMN's regulatory status shifted in 2025; NR (Niagen) has an established supplement pathway.
- Discuss with a clinician if you take other medications or have cancer history.
Questions to ask a licensed clinician
- Is there meaningful clinical evidence of benefit for my goals?
- Are there interactions with my current medications?
- Which form (NMN vs NR) has better safety and quality data?
- Are there quality-verified brands worth considering?
- What outcomes, if any, could realistically be expected?
Sources
Primary and authoritative sources
- 1.Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) — PMC / NCBI (peer-reviewed trial). Clinical studyAccessed July 24, 2026.
- 2.FDA Declares Nicotinamide Mononucleotide Is a Dietary Supplement — Venable LLP (legal/regulatory analysis), October 1, 2025. Reputable secondary source(operational fact only — not independent evidence of safety or efficacy)Accessed July 24, 2026.
Reviewed by Peptides Clarified Editorial — Editorial sourcing review — licensed clinical review pending.